Secondary Hyperparathyroidism in Dialysis: Calcimimetic or Active Vitamin D First
A single patient on dialysis whose parathyroid hormone keeps climbing despite standard measures. The disagreement is between two drug classes that lower PTH by pulling his calcium and phosphate in opposite directions.
Roscoe P., a 61-year-old man, has been on in-center hemodialysis three times a week for just over four years, ever since his kidneys failed following two decades of poorly controlled hypertension. He has kept up part-time bookkeeping for a small trucking company, working around his dialysis schedule with what his nephrologist describes as more discipline than most patients manage.
His PTH is 782 pg/mL, up from 540 six months ago and well above target for his population. His corrected calcium has drifted to 10.3 over the same stretch, toward the upper end of the acceptable range, and it has done so independent of anything the team changed. His phosphate, at 4.8, has stayed well controlled on his current binder regimen, and his 25-OH vitamin D at 34 is replete. Read one at a time these are unremarkable dialysis numbers; read against each other they point in incompatible directions, which is the problem. The three-month-old paricalcitol increase is the piece the group keeps returning to. His PTH went from 540 to 782 across a window that included a dose escalation, which means the escalation has already been tried and has already failed to bend the curve — and his calcium drifted upward across that same window. Whatever is driving his PTH is not responding to more of what he is already taking, and more of it costs him calcium he cannot spare, because active vitamin D analogs raise calcium and phosphate as part of how they work. A calcimimetic moves the other way, lowering PTH while also lowering serum calcium. The evidence for that class in this population is worth stating carefully rather than invoking loosely: EVOLVE, the largest calcimimetic outcome trial in dialysis patients, did not meet its primary composite cardiovascular endpoint in the prespecified unadjusted intention-to-treat analysis, and what its prespecified secondary analysis actually supports, once baseline imbalances are accounted for, is a reduction in clinical fracture — a bone-relevant signal rather than a cardiovascular one, generated with cinacalcet rather than the agent now being proposed for him.
Two directions to move the same number
I'd add a calcimimetic rather than push the vitamin D analog further. Etelcalcetide lowers PTH by increasing calcium-sensing receptor sensitivity, which lowers serum calcium as part of how it works — and given where his calcium has been trending, that direction is actively useful, not just a side effect to manage. I'd be careful how I cite EVOLVE for this, though: it missed its primary cardiovascular endpoint outright, and what it actually supports is a fracture signal in its adjusted secondary analysis, in a trial that used cinacalcet rather than the agent I'm proposing.
My instinct was to increase the paricalcitol further — it directly suppresses PTH synthesis at the gland, and his phosphate is genuinely well-controlled right now, which is usually the reason to hold off on a calcimimetic.
I take the calcium trend seriously, though — active vitamin D analogs raise both calcium and phosphate as part of their mechanism, and if his calcium is already drifting upward independent of anything we've changed, pushing that dose further moves in exactly the wrong direction relative to where he's headed.
That's the piece I'd weight most heavily. His phosphate control is a real, current strength — but his calcium trajectory is the more forward-looking signal, since it's been climbing for six months independent of any intervention. Choosing a drug that would compound that trend solves today's phosphate number at the likely cost of tomorrow's calcium problem.
Adding etelcalcetide, a different mechanism than what he's already on, moves opposite to his current trajectory rather than accelerating it — the new-drug-class monitoring burden is real, but it's the better-aligned choice given where his numbers are actually headed.
Agreed: add etelcalcetide rather than increase the paricalcitol dose, with calcium monitored closely at each dialysis session given the calcimimetic's own hypocalcemia risk on top of a starting calcium already near the upper range.
Not fully settled: how much of a PTH decline within the first month would count as an adequate response before considering combining both drug classes — the nephrologist and endocrinologist named different numeric thresholds informally, without the group converting either into a documented protocol.